Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches
Retrieved on:
Wednesday, March 23, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, IIF, Temperature, Vaccination, Trial of the century, Refrigeration, Organic acid, Transport, University, Coronavirus, Skin, Vaccine, MacLellan, Cockrell School of Engineering, Biotechnology, Globe, Severe acute respiratory syndrome coronavirus 2, CEO, Omicron, United, Science Advances, Innovation, Immune system, University of Sydney School of Molecular Bioscience, BARDA, Safety, NIH, Infection, UT, COVID-19, Biomedical Advanced Research and Development Authority, Department, Development, Efficiency, Moses Austin, Pharmaceutical industry, University of Texas at Austin, Chemistry, Science, SPIKE PROTEINS AND HEXAPRO, VAXXAS’ HD-MAP TECHNOLOGY, VAXXAS
Vaxxas , a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that The University of Texas at Austin has granted Vaxxas an exclusive license to a next-generation SARS-CoV-2 spike subunit vaccine (HexaPro), for vaccination using a patch.
Key Points:
- Vaxxas , a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that The University of Texas at Austin has granted Vaxxas an exclusive license to a next-generation SARS-CoV-2 spike subunit vaccine (HexaPro), for vaccination using a patch.
- We can now rapidly advance our clinical trials with our next-generation COVID-19 vaccine patch.
- Vaxxas plans to complete a Phase 1 clinical study of its proprietary HexaPro/HD-MAP COVID-19 vaccine this year.
- "The current pandemic has underscored the lifesaving potential of innovative technologies, and we think novel vaccination approaches clearly offer unique benefits.